therapeutics to improve cardiovascular health
Amarin Corporation plc is a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health. Amarin's product development program leverages its extensive experience in lipid science and the potential therapeutic benefits of polyunsaturated fatty acids. Vascepa® (icosapent ethyl) is Amarin's first FDA approved product and is available in the United States by prescription. For more information about Vascepa visit www.vascepa.com.
05 Jan 2017
Amarin Provides Preliminary 2016 Results and 2017 Outlook MORE
16 Dec 2016
Amarin Announces Contractual Reminder of Optional Put to Holders of $15.1 million Principal Amount of Outstanding 3.50% Exchangeable Senior Notes Due 2032 MORE
- AMRN (NASDAQ)
- Fri, 20 Jan 2017 16:00
Join Our Mailing List
You may automatically receive Amarin Corporation plc financial information by email.